Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xinnaoshutong
- Development stage
- Phase 4
- Lead developer
- Jilin Aodong Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Xinnaoshutong is a Chinese patent medicine primarily composed of total saponins extracted from the fruit of *Tribulus terrestris* L. It is widely used in China for the treatment of cardiovascular and cerebrovascular diseases, including coronary heart disease, angina pectoris, and ischemic stroke. The drug is thought to exert its therapeutic effects by inhibiting platelet aggregation, improving blood rheology, and protecting vascular endothelial cells. It is often studied in the context of post-stroke recovery and the management of atherosclerosis.
- Brand names
- Xinnaoshutong心脑舒通
- Other names
- Xinnaoshutong capsule心脑舒通胶囊Tribulus terrestris saponins
Beyond the preview
Go deeper on xinnaoshutong.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xinnaoshutong.